View More Recent Stories

Nov 6, 2025 08:06AM Erasca receives US patent for pan-RAS molecular glue ERAS-0015
Oct 15, 2025 04:09PM Stifel Starts Erasca Inc (ERAS) at Buy
Sep 3, 2025 06:10AM BofA Securities Double Downgrades Erasca Inc (ERAS) to Underperform
Aug 18, 2025 03:38AM Morgan Stanley Downgrades Erasca Inc (ERAS) to Equalweight
Aug 12, 2025 05:59PM Erasca, Inc. (ERAS) Reports In-Line Q2 EPS
Aug 12, 2025 04:49PM Erasca, Inc (ERAS) Files $500M Mixed Shelf
Jun 2, 2025 08:06AM Erasca, Inc (ERAS) Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
May 13, 2025 04:07PM Erasca, Inc. (ERAS) Tops Q1 EPS by 2c
May 13, 2025 08:04AM Erasca, Inc (ERAS) Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
Mar 26, 2025 06:01AM Raymond James Starts Erasca Inc (ERAS) at Outperform, PT $5
Mar 20, 2025 04:03PM Erasca, Inc. (ERAS) Tops Q4 EPS by 2c
Dec 12, 2024 01:16PM Clear Street Starts Erasca Inc (ERAS) at Buy
Nov 18, 2024 03:21AM Jefferies Starts Erasca Inc (ERAS) at Buy
Nov 12, 2024 04:04PM Erasca, Inc. (ERAS) Tops Q3 EPS by 6c
Oct 25, 2024 05:44AM Erasca Inc (ERAS) PT Raised to $3.50 at Goldman Sachs
Oct 24, 2024 08:02AM Erasca, Inc (ERAS) Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Aug 13, 2024 01:52PM Erasca Inc (ERAS) PT Lowered to $3 at Goldman Sachs
Aug 13, 2024 06:11AM Erasca Inc (ERAS) PT Raised to $6 at H.C. Wainwright
Aug 12, 2024 04:03PM Erasca, Inc. (ERAS) Misses Q2 EPS by 11c
View More Recent Stories